Royal Bank of Canada restated their underperform rating on shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) in a report published on Wednesday morning, The Fly reports.
Several other equities research analysts have also recently commented on the stock. Barclays reissued an overweight rating on shares of RECKITT BENCKIS/S in a research report on Tuesday, June 23rd. JPMorgan Chase & Co. reissued an overweight rating on shares of RECKITT BENCKIS/S in a research report on Friday, June 26th. Zacks Investment Research raised RECKITT BENCKIS/S from a hold rating to a buy rating and set a $18.00 price target on the stock in a research report on Thursday, May 7th. Morgan Stanley reiterated an overweight rating on shares of RECKITT BENCKIS/S in a research note on Monday, June 15th. Finally, Berenberg Bank reissued a buy rating on shares of RECKITT BENCKIS/S in a research note on Friday, July 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $18.00.
Shares of RBGLY stock opened at $20.41 on Wednesday. RECKITT BENCKIS/S has a 12 month low of $12.76 and a 12 month high of $21.00. The company’s fifty day simple moving average is $18.94 and its 200-day simple moving average is $16.93. The firm has a market cap of $72.40 billion, a PE ratio of 22.68 and a beta of 0.71. The company has a quick ratio of 0.42, a current ratio of 0.56 and a debt-to-equity ratio of 0.91.
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: Derivative
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.